Dosimetry Results for Fetuses in Present Study Compared with Cases Previously Reported in the Literature
| Fetus | Stage of gestation | Mother’s weight (kg) | Injected activity (MBq) | Machine | Phantom (trimester) | Fraction | Time-integrated activity (Bq h/Bq) | Dose (mGy/MBq) | Reference |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 5 wk | 86 | 296 | PET/CT | Nonpregnant | 0.0012 | 0.0030 | 1.73E–02 | (21) |
| 2 | 6 wk | 68 | 583 | PET | Nonpregnant | 0.0036 | 0.0095 | 3.14E–02 | (22) |
| 3 | 8 wk | 60 | 320 | PET/CT | Nonpregnant | 0.0020 | 0.0053 | 2.23E–02 | (3) |
| 4 | 9 wk | 50 | 144 | PET/MRI | Nonpregnant | 0.0019 | 0.0052 | 2.21E–02 | This study |
| 5 | 10 wk | 71 | 296 | PET/CT | Nonpregnant | 0.0018 | 0.0046 | 2.08E–02 | (23) |
| 6 | 12 wk | 58 | 385 | PET/CT | 1 | 0.0006 | 0.0016 | 7.25E–03 | (21) |
| 7 | ∼12 wk | 77 | 350 | PET | 1 | 0.0010 | 0.0026 | 7.70E–03 | (21) |
| 8 | 13 wk | 64 | 178 | PET/MRI | 1 | 0.0005 | 0.0013 | 7.11E–03 | This study |
| 9 | 13 wk | 53 | 209 | PET/MRI | 1 | 0.0007 | 0.0020 | 7.43E–03 | This study |
| 10 | 13 wk | 52 | 205 | PET/MRI | 1 | 0.0009 | 0.0024 | 7.61E–03 | This study |
| 11 | 14 wk | 86 | 333 | PET/MRI | 2 | 0.0013 | 0.0035 | 3.69E–03 | This study |
| 12 | 14 wk | 48 | 187 | PET/MRI | 2 | 0.0018 | 0.0047 | 3.87E–03 | This study |
| 13 | 14 wk | 49 | 199 | PET/MRI | 2 | 0.0018 | 0.0048 | 3.88E–03 | This study |
| 14 | 15 wk | 59 | 235 | PET/MRI | 2 | 0.0028 | 0.0063 | 4.10E–03 | This study |
| 15 | 18 wk* | 67 | 189 | PET/MRI | 2 | 0.0040 | 0.0106 | 4.72E–03 | This study |
| 16 | 18 wk† | 88 | 200 | PET | 2 | 0.0009 | 0.0023 | 3.52E–03 | (22) |
| 17 | 19 wk | 51 | 348 | PET/MRI | 2 | 0.0024 | 0.0063 | 4.10E–03 | (21) |
| 18 | 19 wk | 70 | 296 | PET/MRI | 2 | 0.0037 | 0.0097 | 4.59E–03 | (21) |
| 19 | 19 wk | 50 | 197 | PET/MRI | 2 | 0.0059 | 0.0157 | 5.46E–03 | This study |
| 20 | 19 wk | 48 | 187 | PET/MRI | 2 | 0.0055 | 0.0145 | 5.28E–03 | This study |
| 21 | 21 wk | 53 | 181 | PET/CT | 2 | 0.0049 | 0.0129 | 5.05E–03 | (24) |
| 22 | 23 wk | 59 | 181 | PET | 2 | 0.0078 | 0.0206 | 6.17E–03 | (22) |
| 23 | 24 wk* | 70 | 291 | PET/MRI | 2 | 0.0135 | 0.0356 | 8.33E–03 | This study |
| 24 | 25 wk | 67 | 337 | PET | 2 | 0.0084 | 0.0222 | 6.40E–03 | (22) |
| 25 | 25 wk‡ | 76 | 188 | PET/CT | 2 | 0.0156 | 0.0412 | 9.14E–03 | (4) |
| 26 | 25 wk‡ | 76 | 188 | PET/CT | 2 | 0.0164 | 0.0434 | 9.46E–03 | (4) |
| 27 | 26 wk | 81 | 242 | PET/CT | 2 | 0.0129 | 0.0340 | 8.10E–03 | (25) |
| 28 | 28 wk | 82 | 174 | PET | 3 | 0.0071 | 0.0187 | 3.38E–03 | (22) |
| 29 | ∼28 wk | 66 | 296 | PET | 3 | 0.0195 | 0.0515 | 6.22E–03 | (21) |
| 30 | 30 wk† | 89 | 229 | PET | 3 | 0.0196 | 0.0518 | 6.24E–03 | (22) |
| 31 | 34 wk | 95 | 555 | PET/CT | 3 | 0.0192 | 0.0507 | 6.15E–03 | (26) |
↵*, † = Women imaged twice during pregnancy.
↵‡ Twin pregnancy.
Dosimetry results for fetuses in present study are italicized; cases previously reported in the literature are not italicized. References show publication in which the cases were originally described. Doses may differ from those reported in original publication, when they were reanalyzed in a standardized way (4).